Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Incidence and mortality of multiple myeloma in China, 2006–2016: an analysis of the Global Burden of Disease Study 2016
Jiangmei Liu, Weiping Liu, Lan Mi, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 107

Showing 1-25 of 107 citing articles:

Leukemia incidence trends at the global, regional, and national level between 1990 and 2017
Ying Dong, Oumin Shi, Quan-Xiang Zeng, et al.
Experimental Hematology and Oncology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 249
National and subnational trends in cancer burden in China, 2005–20: an analysis of national mortality surveillance data
Jinlei Qi, Menglong Li, Lijun Wang, et al.
The Lancet Public Health (2023) Vol. 8, Iss. 12, pp. e943-e955
Open Access | Times Cited: 219
BCMA-targeted immunotherapy for multiple myeloma
Bo Yu, Tianbo Jiang, Delong Liu
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 160
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor–T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)
Jian‐Qing Mi, Wanhong Zhao, Hongmei Jing, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 6, pp. 1275-1284
Closed Access | Times Cited: 43
The Burden of Multiple Myeloma in China: Trends from 1990 to 2021 and Forecasts for 2050
Xuelin Dou, Guangcai Duan, You Zhong, et al.
Cancer Letters (2025) Vol. 611, pp. 217440-217440
Closed Access | Times Cited: 1
A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast
Qiang Hou, Xinyang Li, Huanxin Ma, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Emerging agents and regimens for multiple myeloma
Yang Yang, Yi Li, Huiyao Gu, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 69
Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma
Chunmei Kuang, Meijuan Xia, Gang An, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 18
Identification of a novel lactylation-related gene signature predicts the prognosis of multiple myeloma and experiment verification
Cheng Sun, Wanqiu Zhang, Hao Liu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Global, regional, and national burdens of leukemia from 1990 to 2017: a systematic analysis of the global burden of disease 2017 study
Xiangjie Lin, Jinghan Wang, Xin Huang, et al.
Aging (2021) Vol. 13, Iss. 7, pp. 10468-10489
Open Access | Times Cited: 39
Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
Xiaoyan Qu, Gang An, Weiwei Sui, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 9, pp. e005145-e005145
Open Access | Times Cited: 25
Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study
Weijun Fu, Soo‐Mee Bang, Honghui Huang, et al.
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 6, pp. 446-455.e4
Closed Access | Times Cited: 14
Global disparities in patients with multiple myeloma: a rapid evidence assessment
María‐Victoria Mateos, Sikander Ailawadhi, Luciano J. Costa, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 14
Novel methyltransferase G9a inhibitor induces ferroptosis in multiple myeloma through Nrf2/HO-1 pathway
Yu Zhang, Xiaoshun Wang, Xiaoqi Li, et al.
Annals of Hematology (2024) Vol. 103, Iss. 7, pp. 2405-2417
Open Access | Times Cited: 5
Hematopoietic stem cell microtransplantation: current situation and challenges
Zhengyang Li, Yuanyuan Yang, Hongwei Peng, et al.
Therapeutic Advances in Hematology (2025) Vol. 16
Open Access
Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma
Kaili Chen, Huixin Liang, Zeyuan Yu, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Performance and efficiency of Machine learning models in analyzing capillary serum protein electrophoresis
Xia Wang, Mei Zhang, Chuan Li, et al.
Clinica Chimica Acta (2025), pp. 120165-120165
Closed Access
Global, regional and national epidemiological trends of multiple myeloma from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021
Linmin Zhuge, Xiaowu Lin, Ziwei Fan, et al.
Frontiers in Public Health (2025) Vol. 13
Open Access
Profilin 1 induces drug resistance by downregulating CD138 expression via autophagy in multiple myeloma
Ya Wang, Zhen Dai, Shengying Xiao, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma
Qiong Li, Wei Zhang, Jiali Li, et al.
Biomarker Research (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 32
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study
Jin Lu, Weijun Fu, Wei Li, et al.
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 21, Iss. 9, pp. e699-e709
Open Access | Times Cited: 30
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
Lugui Qiu, Zhongjun Xia, Chengcheng Fu, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 20
A population-based study on incidence trends of myeloma in the United States over 2000–2020
Seyed Ehsan Mousavi, Mehran Ilaghi, Armin Aslani, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma
Tian Xia, Ming Liu, Quan Zhao, et al.
Cell Death and Disease (2021) Vol. 12, Iss. 10
Open Access | Times Cited: 26
G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt/β-catenin pathway
Rui Li, Mengying Ke, Qi Mingming, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top